Xiuning Le, MD, PhD

Xiuning Le, MD, PhD, assistant professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center in Houston, Texas discusses the limited treatment options available for patients with non–small cell lung cancer (NSCLC) and an 

There is currently no FDA approved agent to treat patients with 

 or HER2 exon 20-positive NSCLC. Targeting these oncogenes is a great unmet medical need, explains Le, and although chemotherapy is still an option to treat patients with 

-positive NSCLC, it is important use all the tools that are available to treat this patient population.

Introducing a small molecule tyrosine kinase inhibitor such as poziotinib is important for the future treatment of 

 and HER exon 20-positive NSCLC. The hope is to bring more options to field.

Videos

Xiuning Le, MD, PhD, discusses the limited treatment options available for patients with non–small cell lung cancer and an EGFR exon 20 mutation.










Filling in the Treatment Gap for Patients With EGFR+ NSCLC

Xiuning Le, MD, PhD, an assistant professor in the Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses the results of tepotinib (Tepmetko) in patients with advanced non-small cell lung cancer (NSCLC) and a MET exon 14 skipping mutation.

The phase 2 VISION trial (NCT02864992) was massively positive, says Le. In the 99 patients the investigators could report on, there was about 46% objective response rate. To get a real response, she says the tumor has to shrink by at least 30%. In the 99 patients, there was 90% tumor shrinkage.

Le says the hypothesis for the study was correct due to these findings. The small molecule inhibitor tepotinib works on the tumor and induces tumor shrinkage. There were some patients with more tumor shrinkage than others on the trial, but overall the results were positive and showed that tepotinib works for this patient population.

There was a median progression-free survival of 8.6 months with this drug by independent review committee and 9.5 months by investigator assessment.

<< View more resources regarding lung cancers

Xiuning Le, MD, PhD, discusses the results of tepotinib in patients with advanced non-small cell lung cancer and a MET exon 14 skipping mutation.

Xiuning Le, MD, PhD | Authors

Articles

Filling in the Treatment Gap for Patients With EGFR+ NSCLC

VISION Trial Produces Positive Data in NSCLC With MET Exon 14 Mutations